Breaking Finance News

Alexion Pharmaceuticals Inc. (NDAQ:ALXN) price target upped to $182.00, released a report earlier today by Leerink Swann

Boasting a price of $145.34, Alexion Pharmaceuticals Inc. (NDAQ:ALXN) traded 0.05% higher on the day. With the last stock price close up 16.01% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Alexion Pharmaceuticals Inc. has recorded a 50-day average of $137.20 and a two hundred day average of $124.25. Volume of trade was down over the average, with 283,478 shares of ALXN changing hands under the typical 2,140,180

Leerink Swann bumped up the target of Alexion Pharmaceuticals Inc. (NDAQ:ALXN) to $182.00 stating a potential upside of 0.25%.

See Chart Below

Alexion Pharmaceuticals Inc. (NDAQ:ALXN)

Alexion Pharmaceuticals Inc. has a one year low of $96.18 and a one year high of $149.34 with a PE ratio of 62.51 Alexion Pharmaceuticals Inc.’s market capitalization is currently $0.

Also covering Alexion Pharmaceuticals Inc.'s price target, a total of 18 brokerages have released a ratings update on ALXN. The one year target is $187.61 with seven brokers rating the stock a strong buy, 6 brokers rating the stock a buy, 7 firms rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

More About Alexion Pharmaceuticals Inc. (NDAQ:ALXN)

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.